Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
ONJ has been increasingly suspected to be a potential complication of bisphosphonate therapy in recent years. Thus, the ASBMR leadership appointed a multidisciplinary task force to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder. This report summarizes the findings and recommendations of the task force. Introduction: The increasing recognition that use of bisphosphonates may be associated with osteonecrosis of the jaw (ONJ) led the leadership of the American Society for Bone and Mineral Research (ASBMR) to appoint a task force to address a number of key questions related to this disorder. Materials and Methods: A multidisciplinary expert group reviewed all pertinent published data on bisphosphonate-associated ONJ. Food and Drug Administration drug adverse event reports were also reviewed. Results and Conclusions: A case definition was developed so that subsequent studies could report on the same condition. The task force defined ONJ as the presence of exposed bone in the maxillofacial region that did not heal within 8 wk after identification by a health care provider. Based on review of both published and unpublished data, the risk of ONJ associated with oral bisphosphonate therapy for osteoporosis seems to be low, estimated between 1 in 10,000 and <1 in 100,000 patient-treatment years. However, the task force recognized that information on incidence of ONJ is rapidly evolving and that the true incidence may be higher. The risk of ONJ in patients with cancer treated with high doses of intravenous bisphosphonates is clearly higher, in the range of 1–10 per 100 patients (depending on duration of therapy). In the future, improved diagnostic imaging modalities, such as optical coherence tomography or MRI combined with contrast agents and the manipulation of image planes, may identify patients at preclinical or early stages of the disease. Management is largely supportive. A research agenda aimed at filling the considerable gaps in knowledge regarding this disorder was also outlined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The risk of ONJ appears to increase with duration of treatment beyond 5 years [77].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [77]
Citations
Cites
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Self-citationMarx, R. E., Sawatari, Y., Fortin, M., & Broumand, V. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.07.010 · Cited by 1,648 · cited 1×
“P (5) A + P (1) Max (5) Marx et al.((23)) 3 O (3) A (3) Marunick et al.”
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252 · cited 2×
“● Surgical management: ● Surgical treatment should be conservative or delayed.((12,37,38))”
BackgroundSelf-citationOsteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8670 · Cited by 1,149 · cited 1×
“However, for those who received zoledronic acid alone, the hazard was 1% within the first year but rose to 21% at 3 yr.((18))”
BackgroundHillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Self-citationOsteonecrosis of the Jaw and Bisphosphonates
(2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530120 · Cited by 744
Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia
Mavrokokki, T., Cheng, A., Stein, B., & Goss, A. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.10.061 · Cited by 650
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542 · cited 2×
“The American Society of Clinical Oncology (ASCO) has established guidelines for the use of bisphosphonates in patients with metastatic breast cancer and multiple myeloma.((7,8)) The ASCO guidelines suggest that once the bisphosphonate is initiated, it should be continued until there is substantial decline in the patie…”
BackgroundRuggiero, S. L., Fantasia, J., & Carlson, E. (2006) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2006.06.004 · Cited by 507
Self-citationManaging the care of patients with bisphosphonate-associated osteonecrosis
MIGLIORATI, C. A., CASIGLIA, J., EPSTEIN, J., JACOBSEN, P. L., SIEGEL, M. A., & WOO, S.-B. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0108 · Cited by 468
Self-citationBisphosphonates: Clinical Experience
Coleman, R. E. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-14 · Cited by 384
State-of-the-art on cone beam CT imaging for preoperative planning of implant placement
Guerrero, M. E., Jacobs, R., Loubele, M., Schutyser, F., Suetens, P., & van Steenberghe, D. (2006) · Clinical Oral Investigations · doi:10.1007/s00784-005-0031-2 · Cited by 371
Ruggiero, S. L., Gralow, J. R., Marx, R. E., Hoff, A. O., Schubert, M. M., Huryn, J. M., Toth, B., Damato, K., & Valero, V. (2006) · Journal of Oncology Practice · doi:10.1200/jop.2.1.7 · Cited by 355
Self-citationPolarization–Sensitive Optical Coherence Tomography of Dental Structures
Baumgartner, A., Dichtl, S., Hitzenberger, C. K., Sattmann, H., Robl, B., Moritz, A., Fercher, A. F., & Sperr, W. (2000) · Caries Research · doi:10.1159/000016571 · Cited by 235 · cited 1×
“0 mm)((32)) and the resolution of the scanning beams (from 10 to 17 m).((33,34)) One advantage is that it does not use ionizing radiation.”
BackgroundDental management of patients receiving oral bisphosphonate therapy
(2006) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2006.0355 · Cited by 232
Mandibular osteoradionecrosis: clinical behaviour and diagnostic aspects
Store, G., & Boysen, M. (2000) · Clinical Otolaryngology and Allied Sciences · doi:10.1046/j.1365-2273.2000.00367.x · Cited by 225
Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws
Chiandussi, S., Biasotto, M., Dore, F., Cavalli, F., Cova, M., & Di Lenarda, R. (2006) · Dentomaxillofacial Radiology · doi:10.1259/dmfr/27458726 · Cited by 224
Bisphosphonates and osteonecrosis of the jaw
Purcell, P. M., & Boyd, I. W. (2005) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06762.x · Cited by 202
Osteonecrosis of the Mandible or Maxilla Associated with the use of New Generation Bisphosphonates
Farrugia, M. C., Summerlin, D., Krowiak, E., Huntley, T., Freeman, S., Borrowdale, R., & Tomich, C. (2006) · The Laryngoscope · doi:10.1097/01.mlg.0000187398.51857.3c · Cited by 167
Bisphosphonates and avascular necrosis of the jaw: a possible association
Carter, G., Goss, A. N., & Doecke, C. (2005) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06761.x · Cited by 156 · cited 1×
“Max (1) Carter et al.((48)) 3 P (3) A (1), P (2) Max (3) Pozzi et al.”
Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy
Melo, M. D., & Obeid, G. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0110 · Cited by 151
Starck, W. J., & Epker, B. N. (1995) · PubMed · Cited by 151
A Review of Potential New Diagnostic Modalities for Caries Lesions
Hall, A. F., & Girkin, J. M. (2004) · Journal of Dental Research · doi:10.1177/154405910408301s18 · Cited by 135 · cited 1×
“0 mm)((32)) and the resolution of the scanning beams (from 10 to 17 m).((33,34)) One advantage is that it does not use ionizing radiation.”
BackgroundOsteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy
Hoff, A. O., Toth, B. B., Altundag, K., Guarneri, V., Adamus, A., Nooka, A. K., Sayegh, G. G., Johnson, M. M., Gagel, R. F., & Hortobagyi, G. N. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8528 · Cited by 133
Self-citationThe dental implications of bisphosphonates and bone disease
Cheng, A., Mavrokokki, A., Carter, G., Stein, B. N., Fazzalari, N. L., Wilson, D., & Goss, A. N. (2005) · Australian Dental Journal · doi:10.1111/j.1834-7819.2005.tb00384.x · Cited by 121
Larheim, T. A., Westesson, P., Hicks, D. G., Eriksson, L. I., & Brown, D. A. (1999) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(99)90001-0 · Cited by 115 · cited 1×
“Nonetheless, to date, available data on MRI findings of bisphosphonate-associated ONJ are limited and suggest that this technique may be associated with a high percentage of false-positive diagnoses.((31))”
BackgroundOsteonecrosis of the Jaw: More Research Needed
Shane, E. J., Goldring, S. R., Christakos, S., McKee, M. D., Eisman, J. A., Silverman, S. L., & Pendrys, D. G. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060712 · Cited by 96 · cited 5×
“1 75 1F O (1) E Mand (1) Hoefert et al.”
BackgroundInfluentialSelf-citationZavras, A. I., & Zhu, S. (2006) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.02.011 · Cited by 85 · cited 1×
“05).((17)) In a prospective clinical trial performed in Greece of 252 patients with a variety of cancers who had received at least 6 mo of bisphosphonate therapy, the risk of developing bisphosphonate-associated ONJ increased with longer exposure to bisphosphonate therapy and was associated with the bisphosphonate use…”
BackgroundSchulze, D., Blessmann, M., Pohlenz, P., Wagner, K., & Heiland, M. (2006) · Dentomaxillofacial Radiology · doi:10.1259/dmfr/71331738 · Cited by 84 · cited 1×
“Cone beam CT: Cone beam CT (CBCT) is a relatively new technique that imparts lower radiation to oral tissues (<1/15 that of a spiral CT), but has higher spatial resolution than conventional CT and provides better image quality, particularly for cancellous bone.((28,29)) Although it may be limited in its discrimination…”
BackgroundBisphosphonates and osteonecrosis of the jaw.
Sambrook, P. N., Olver, I., & Goss, A. N. (2006) · PubMed · Cited by 73
Effectiveness and cost of bisphosphonate therapy in tumor bone disease
Body, J. (2003) · Cancer · doi:10.1002/cncr.11139 · Cited by 72 · cited 2×
“Bisphosphonates have been shown to decrease the risk of skeletal complications by approximately one third.((5)) In addition, bisphosphonates are clinically important for the treatment of hypercalcemia of malignancy and can reduce cancer induced bone pain.”
BackgroundGabriel, H. A., Fitzgerald, S. W., Myers, M. T., Donaldson, J. S., & Poznanski, A. K. (1994) · Radiographics · doi:10.1148/radiographics.14.4.7938767 · Cited by 57 · cited 1×
“Additionally, the general consensus is that marrow edema is not part of the pathogenesis of bisphosphonate-associated ONJ, as it is for AVN, considerations that may limit the use of MR in the diagnosis of ONJ.((30)) The region of ischemia can be recognized, however, as a nonenhanced area after the use of a contrast ag…”
BackgroundImaging of the Oral Cavity Using Optical Coherence Tomography
Colston, B. W., Everett, M., Sathyam, U. S., DaSilva, L. B., & Otis, L. L. (2000) · KARGER eBooks · doi:10.1159/000061643 · Cited by 54 · cited 1×
“0 mm)((32)) and the resolution of the scanning beams (from 10 to 17 m).”
BackgroundMandibular osteoradionecrosis: a comparison of computed tomography with panoramic radiography
Støre, G., & Larheim, T. A. (1999) · Dentomaxillofacial Radiology · doi:10.1038/sj/dmfr/4600461 · Cited by 52
Bisphosphonates and Osteonecrosis of the Jaw
Woo, S., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-10-200611210-00023 · Cited by 48
Self-citationEstilo, C. L., Poznak, C. H. V., Williams, T. L., Evtimovska, E., Tkach, L., Halpern, J., Tunick, S., & Huryn, J. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.8088 · Cited by 47
Mandibular osteoradionecrosis: a comparison of computed tomography with panoramic radiography
Støre, G., & Larheim, T. A. (1999) · Dentomaxillofacial Radiology · doi:10.1038/sj.dmfr.4600461 · Cited by 35
Bisphosphonates in the prevention and treatment of bone metastases.
Ramaswamy, B., & Shapiro, C. L. (2003) · PubMed · Cited by 28
Pozzi, S., Marcheselli, R., Sacchi, S., Quarta, G., Musto, P., Caparrotti, G., Natale, D., Pianezze, G., Polimeno, G., Pitini, V. V., et al. (2005) · Blood · doi:10.1182/blood.v106.11.5057.5057 · Cited by 26
Ostéonécrose des maxillaires chez des patients traités par bisphosphonates
Najm, S. A., Lysitsa, S. N., Carrel, J. P., Lesclous, P., Lombardi, T., & SAMSON, J. A. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84119-3 · Cited by 25
Adverse oral sequelae to bisphosphonate administration.
Marunick, M. T., Miller, R. E., & Gordon, S. C. (2005) · PubMed · Cited by 23
Nekrosen der Kieferknochen unter Bisphosphonattherapie
Hoefert, S., & Eufinger, H. (2005) · Der Orthopäde · doi:10.1007/s00132-005-0901-y · Cited by 11 · cited 1×
“1 75 1F O (1) E Mand (1) Hoefert et al.((46)) 3 O (3) Najm et al.”
(2002) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2002.0308 · Cited by 5
Research works printed but not linked: 3
- Felsenberg, 2006, Bisphosphonattherapie assoziierte, Kiefernekrosen Deutsches Arzteblatt, 46, A3078
- Van Poznak, 2004, Osteonecrosis of the maxilla and mandible in patients with metastatic breast cancer, J Bone Miner Res, 19, S227
- Ruggiero, 2004, Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg, 62, 527, 10.1016/j.joms.2004.02.004 · DOI · Paper page
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
“The risk of ONJ appears to increase with duration of treatment beyond 5 years [77].”
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Self-citationWells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
“Side effects of these potent antiresorptives include osteonecrosis of the jaw, atypical subtrochanteric fractures, and hypocalcemia (323,324).”
Self-citationShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citation
Metadata
- Authors
- Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., McCauley, L. K., McGowan, J., McKee, M. D., Mohla, S., Pendrys, D. G., Raisz, L. G., Ruggiero, S. L., Shafer, D. M., Shum, L., Silverman, S. L., Van Poznak, C. H., Watts, N., Woo, S.-B., & Shane, E.
- Affiliations
- American Society for Bone and Mineral Research (US)
- ASBMR Task Force on Bisphosphonate-Associated ONJ
- Corresponding author
- Shane, Elizabeth
- ORCID
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 22
- Issue
- 10
- Pages
- 1479-1491
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2150904792
- Cited by
- 1,650
- References
- 43
- Citations by year
- 2026: 20 · 2025: 40 · 2024: 41 · 2023: 35 · 2022: 52 · 2021: 45 · 2020: 71 · 2019: 58 · 2018: 58 · 2017: 70 · 2016: 89 · 2015: 114 · 2014: 121 · 2013: 152 · 2012: 118
- FWCI
- 69.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Procter and Gamble
- American Society for Bone and Mineral Research
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Dentistry › General Dentistry › Oral health in cancer treatment
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- bisphosphonate-related osteonecrosis of the jaw, bisphosphonates, osteonecrosis of the jaw, case definition, risk factors, oral bisphosphonates, osteoporosis, cancer patients, intravenous bisphosphonates, diagnostic imaging, optical coherence tomography, magnetic resonance imaging, clinical management, drug adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Americas, Animals, Diagnosis, Differential, Diphosphonates, Female, Humans, Jaw Diseases, Male, Middle Aged, Minerals, Osteonecrosis, Risk Factors, Societies, Medical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.